Spots Global Cancer Trial Database for Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma
Official Title: Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin)
Study ID: NCT01493479
Conditions
Study Description
Brief Summary: 90Y Ibritumomab tiuxetan (zevalin) has demonstrated consistently high response rates in patients who have received previous treatment for lymphoma. More than two-thirds of the patients who achieve CR go on to experience durable remissions lasting for years. Despite these highly promising clinical results with radioimmunotherapy (RIT) in relapsed follicular lymphoma there is very little data using RIT in previously untreated follicular lymphoma. The objective of this trial is to evaluate the safety and efficacy of two fractions of Zevalin in patients with previously untreated follicular lymphoma in a Phase II study.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Centre Hospitalier Universitaire de Lille, Lille, , France
Centre Hospitalier Universitaire de Nantes, Nantes, , France
Centre Henri Becquerel, Rouen, , France
St George's Hospital, London, , United Kingdom
The Christie NHS Foundation Trust, Manchester, , United Kingdom
Poole Hospital NHS Foundation Trust, Poole, , United Kingdom
Southampton University Hospital, Southampton, , United Kingdom
Contact Details
Name: Timothy Illidge, Prof
Affiliation: The Christie NHS Foundation Trust
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
